The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients.

ABSTRACT:

Introduction

With the emergence of SARS-CoV-2 mutant strains, especially the epidemic of Omicron, it continues to evolve to strengthen immune evasion. Omicron BQ. 1 and XBB pose a serious threat to the current COVID-19 vaccine (including bivalent mRNA vaccine for mutant strains) and COVID-19-positive survivors, and all current therapeutic monoclonal antibodies are ineffective against them. Older people, those with multimorbidity, and those with specific underlying health conditions remain at increased risk of COVID-19 hospitalization and death after the initial vaccine booster. However, small-molecule drugs for conserved targets remain effective and urgently needed.

Methods

The non-structural protein of SARS-CoV-2 non-structural protein 1(Nsp1) can bind to the host 40S ribos

SUBMITTER: Shen M 

PROVIDER: S-EPMC10027911 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature